The EvIDHence study: real-world treatment patterns and safety outcomes in mutant and wild-type IDH1 cholangiocarcinoma before availability of mIDH1 inhibitors.

Sahai V, Valle JW, Fares N, Javle M, Ghanem I, Cerdà P, Rapposelli IG, Jimenez IG, Gonzalez-Carmona MA, Hollebecque A, Cid RP, Palmer DH, Vera R, Casadei-Gardini A, Melisi D, Blanc JF, Perkhofer L, Lamarca A, Gharbi H, Manuel-Minguez V, Robert R, Rimassa L

Open source

DOI: 10.1016/j.esmogo.2026.100367
Published: 2026 Sep
Container: ESMO gastrointestinal oncology
Publisher: Not recorded
Open access: yes

Credibility signals

limited evidence Score 45/100 under policy 1.0.0. This is a metadata assessment, not a judgment of the paper's conclusions.

Show all credibility signals

cautionDOI registered: No matching Crossref record was present in this response. Source: Crossref; license: CC0 metadata
cautionDOI resolves: No matching Crossref record was present in this response. Source: Crossref; license: CC0 metadata
not scoredDirectory of Open Access Journals: No matching DOAJ record was present in this response. No allow-list match; this is not evidence of low credibility. Source: DOAJ; license: CC0
not scoredMEDLINE indexed: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredOpenAlex core source: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredKnown publisher allow-list: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredROR affiliation: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredRetraction Watch retraction: No retraction notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete. Source: Retraction Watch; license: CC BY 4.0
not scoredRetraction Watch expression of concern: No expression of concern notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete. Source: Retraction Watch; license: CC BY 4.0
not scoredRetraction Watch correction: No correction notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete. Source: Retraction Watch; license: CC BY 4.0
not scoredRetraction Watch reinstatement: No reinstatement notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete. Source: Retraction Watch; license: CC BY 4.0
supportingOpen access status: Normalized open-access status: open. Source: Normalized work metadata; license: Caller-provided; provenance license not supplied to scorer
not scoredPublication license: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredPublication version: A publication version was supplied but is not scored. Source: Normalized work metadata; license: Caller-provided; provenance license not supplied to scorer
cautionMetadata completeness: 5 of 6 scored descriptive metadata groups are present; missing fields increase uncertainty. Source: Normalized work metadata; license: Caller-provided; provenance license not supplied to scorer

Cite this work

BibTeX

@article{allodium:10.1016/j.esmogo.2026.100367,
  title = {The EvIDHence study: real-world treatment patterns and safety outcomes in mutant and wild-type IDH1 cholangiocarcinoma before availability of mIDH1 inhibitors.},
  author = {Sahai V and Valle JW and Fares N and Javle M and Ghanem I and Cerdà P and Rapposelli IG and Jimenez IG and Gonzalez-Carmona MA and Hollebecque A and Cid RP and Palmer DH and Vera R and Casadei-Gardini A and Melisi D and Blanc JF and Perkhofer L and Lamarca A and Gharbi H and Manuel-Minguez V and Robert R and Rimassa L},
  year = {2026},
  journal = {ESMO gastrointestinal oncology},
  doi = {10.1016/j.esmogo.2026.100367},
  url = {https://doi.org/10.1016/j.esmogo.2026.100367}
}

RIS

TY  - JOUR
TI  - The EvIDHence study: real-world treatment patterns and safety outcomes in mutant and wild-type IDH1 cholangiocarcinoma before availability of mIDH1 inhibitors.
AU  - Sahai V
AU  - Valle JW
AU  - Fares N
AU  - Javle M
AU  - Ghanem I
AU  - Cerdà P
AU  - Rapposelli IG
AU  - Jimenez IG
AU  - Gonzalez-Carmona MA
AU  - Hollebecque A
AU  - Cid RP
AU  - Palmer DH
AU  - Vera R
AU  - Casadei-Gardini A
AU  - Melisi D
AU  - Blanc JF
AU  - Perkhofer L
AU  - Lamarca A
AU  - Gharbi H
AU  - Manuel-Minguez V
AU  - Robert R
AU  - Rimassa L
PY  - 2026
JO  - ESMO gastrointestinal oncology
DO  - 10.1016/j.esmogo.2026.100367
UR  - https://doi.org/10.1016/j.esmogo.2026.100367
ER  -

APA

V, S., JW, V., N, F., M, J., I, G., P, C., IG, R., IG, J., MA, G., A, H., RP, C., DH, P., R, V., A, C., D, M., JF, B., L, P., A, L., H, G., V, M., R, R., & L, R. (2026). The EvIDHence study: real-world treatment patterns and safety outcomes in mutant and wild-type IDH1 cholangiocarcinoma before availability of mIDH1 inhibitors.. ESMO gastrointestinal oncology. https://doi.org/10.1016/j.esmogo.2026.100367

Source records

pubmed · retrieved 2026-09-25T19:27:48.388Z